Where ACADIA Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter, with 2 bullish, 4 somewhat bullish, and 5 indifferent. The average price target is $25.33, implying an upside from the current price of $24.77. This average price target has increased by 16.19% over the past month.
July 11, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals has received various ratings from analysts, with an average price target of $25.33, indicating a potential upside from the current price. The target has increased by 16.19% over the past month.
The average price target given by analysts suggests a potential upside for ACADIA Pharmaceuticals, which is a positive signal for the stock. The increase in the target over the past month indicates growing optimism among analysts, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100